Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RIFAMPIN

All products: general benefit

Other products in the same Health Canada class (J04A, J04AB) — coverage varies; not interchangeable

  • Rifabutin (Mycobutin): limited Use 103, 104, Listing status unconfirmed
  • Ethambutol (Myambutol): general benefit, Not a benefit

Rofact · DIN 00343617 · 300mg · capsule

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Rofact · DIN 00343617 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2019-07-02 · brand ROFACT · ATC J04AB02 RIFAMPICIN · form Capsule · route Oral · ingredients RIFAMPIN 300 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Rofact: Formulary list price $1.4452/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.4452 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2863 · Verify on the e-Formulary ↗ (DIN 00343617)

Source record
DIN 00343617: Rofact Raw flags: sec3=Y Item: 081600008; group id 58; item number 0117; lccId None; manufacturer id VAL Source form: Cap; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $1.4452; ministry $1.4452 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00343617 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2863
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:16 Antitubercular Agents) and how they are covered

Matched class: 08:16 Antitubercular Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ETHAMBUTOL HCL 08:16 Antitubercular Agents

RIFABUTIN

· 2 products · Limited Use, codes 103, 104 (1), Temporary benefit (1) · strengths: 150mg · Cap

ETHAMBUTOL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 400mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:16
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE ROFACT (rifampin) is indicated for the treatment of pulmonary tuberculosis. In order to avoid emergence of resistance, ROFACT must be administered concomitantly with at least one other effective antituberculosis drug. Selection of the appropriate drug combinations should be ROFACT® Prescribing Information Page 3 of 27 determined on the basis of in vitro sensitivity tests, comparative safety as well as the patient's previous clinical history. The following are the most frequently used treatment regimens for previously untreated patients: • ROFACT with Isoniazid • ROFACT with Ethambutol • ROFACT with Isoniazid and Ethambutol The possibility of a drug interaction as well as the individual properties and special precautions relating to drugs used in concomitant therapy should be taken into consideration, e.g., PAS is known to delay the absorption of Rifampin. When such concomitant medication is employed, it is recommended that an interval of 8 to 12 hours between each drug be observed. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ROFACT and othe… https://pdf.hres.ca/dpd_pm/00051995.PDF PM date: not printed or not captured Source product: ROFACT; DIN 00343617; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.